{"id":"topical-testosterone-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions (erythema, irritation)"},{"rate":null,"effect":"Acne"},{"rate":null,"effect":"Polycythemia"},{"rate":null,"effect":"Prostate-related effects"},{"rate":null,"effect":"Gynecomastia"}]},"_chembl":{"chemblId":"CHEMBL1200335","moleculeType":"Small molecule","molecularWeight":"400.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Testosterone is absorbed percutaneously and enters systemic circulation to restore physiological testosterone concentrations. This activates androgen receptors throughout the body, promoting development and maintenance of male sexual characteristics, muscle mass, bone density, and other androgen-dependent functions. The topical formulation allows for controlled, non-invasive hormone replacement therapy.","oneSentence":"Topical testosterone gel delivers testosterone through the skin to replace deficient hormone levels in hypogonadal men.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:17.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone replacement therapy in adult males with hypogonadism"}]},"trialDetails":[{"nctId":"NCT06084338","phase":"PHASE2","title":"Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-12-14","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07260825","phase":"PHASE2, PHASE3","title":"Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"TriHealth Inc.","startDate":"2025-12","conditions":"Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva","enrollment":44},{"nctId":"NCT06455969","phase":"PHASE4","title":"Adaptions and Resiliency to Multi-Stressor OpeRations","status":"RECRUITING","sponsor":"Bradley Nindl","startDate":"2024-07-15","conditions":"Musculoskeletal Injury, Hypogonadism","enrollment":120},{"nctId":"NCT04833426","phase":"PHASE3","title":"Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy","status":"RECRUITING","sponsor":"Canisius-Wilhelmina Hospital","startDate":"2022-12-12","conditions":"Prostatic Neoplasms, Hypogonadism, Testosterone Deficiency","enrollment":140},{"nctId":"NCT04456296","phase":"PHASE4","title":"A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2020-06-30","conditions":"Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism","enrollment":673},{"nctId":"NCT02938923","phase":"PHASE3","title":"Starting a Testosterone and Exercise Program After Hip Injury","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-03-05","conditions":"Hip Fracture, Frailty, Sarcopenia","enrollment":129},{"nctId":"NCT05825092","phase":"PHASE2","title":"Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2023-07-21","conditions":"Critical Illness","enrollment":600},{"nctId":"NCT03198728","phase":"PHASE3","title":"Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Marius Pharmaceuticals","startDate":"2017-07-05","conditions":"Hypogonadism, Male","enrollment":314},{"nctId":"NCT04274894","phase":"PHASE4","title":"A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-12","conditions":"Hypogonadism","enrollment":246},{"nctId":"NCT03000127","phase":"PHASE2","title":"Testosterone for Fatigue in Men With MS","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2018-07-01","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT00365794","phase":"PHASE2","title":"Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2006-08","conditions":"Aging, Obesity, Insulin Resistance","enrollment":22},{"nctId":"NCT03967964","phase":"PHASE1","title":"Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2015-11-20","conditions":"Pharmacokinetics, Hormone Deficiency","enrollment":46},{"nctId":"NCT03783988","phase":"PHASE1","title":"Study With a Topical Gel Containing TRIAC and DHEA in Subjects With Skin Atrophy Due to Glucocorticoids","status":"UNKNOWN","sponsor":"Trophea Development AB","startDate":"2019-01-15","conditions":"Skin Atrophy","enrollment":10},{"nctId":"NCT01403116","phase":"PHASE3","title":"Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2011-07","conditions":"Male Hypogonadism","enrollment":325},{"nctId":"NCT02667561","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodinamic and Safety of Testosterone Gel 1%","status":"WITHDRAWN","sponsor":"Biolab Sanus Farmaceutica","startDate":"2017-07","conditions":"Post-menopausal Period","enrollment":""},{"nctId":"NCT00957801","phase":"PHASE4","title":"Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2009-03","conditions":"Sarcopenia","enrollment":29},{"nctId":"NCT00345969","phase":"PHASE3","title":"Exercise and Testosterone Therapy in Elderly Men With Physical Frailty","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2004-11","conditions":"Physical Frailty, Hip Fracture, Elective Hip Replacement","enrollment":25},{"nctId":"NCT00194675","phase":"PHASE4","title":"TRADE-Testosterone Replacement and Dutasteride Effectiveness","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-03","conditions":"Hypogonadism, Benign Prostatic Hyperplasia","enrollment":53},{"nctId":"NCT02081300","phase":"PHASE3","title":"Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2014-02","conditions":"Male Hypogonadism","enrollment":315},{"nctId":"NCT00240981","phase":"PHASE4","title":"TOM: Testosterone in Older Men With Sarcopenia","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2005-01","conditions":"Sarcopenia, Hypogonadism, Muscular Diseases","enrollment":209},{"nctId":"NCT01386606","phase":"PHASE2","title":"The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2011-06","conditions":"Secondary Hypogonadism","enrollment":60},{"nctId":"NCT00706719","phase":"PHASE2","title":"To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2008-06","conditions":"Secondary Hypogonadism","enrollment":17},{"nctId":"NCT01893281","phase":"PHASE4","title":"The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Hypogonadism","enrollment":78},{"nctId":"NCT01270841","phase":"PHASE2","title":"Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2011-01","conditions":"Secondary Hypogonadism","enrollment":83},{"nctId":"NCT02110368","phase":"PHASE3","title":"Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2014-03","conditions":"Primary Hypogonadism, Hypogonadotropic Hypogonadism","enrollment":32},{"nctId":"NCT01386567","phase":"PHASE2","title":"A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2011-07","conditions":"Hypogonadism, Low Testosterone","enrollment":48},{"nctId":"NCT01408498","phase":"NA","title":"Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance","status":"COMPLETED","sponsor":"University of Texas at Austin","startDate":"2012-01","conditions":"Testosterone's Effects on Threat Perception/Response","enrollment":120},{"nctId":"NCT01143818","phase":"","title":"ESPRIT Study in Hypogonadal Men","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-12","conditions":"Hypogonadism","enrollment":1053}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["T-gel","LY900011","Axiron","Testosterone Solution 2%","Testim"],"phase":"marketed","status":"active","brandName":"topical testosterone gel","genericName":"topical testosterone gel","companyName":"Clarus Therapeutics, Inc.","companyId":"clarus-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical testosterone gel is a small molecule androgen receptor agonist, classified as an agonist. It is used to treat conditions such as hip fracture, frailty, sarcopenia, physical frailty, and elective hip replacement, often in conjunction with supervised exercise training.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-11-23T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":"AXIRON","application_number":"NDA022504"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}